Does chemical shift imaging offer a biomarker for the diagnosis and assessment of disease severity in multiple myeloma?: A cross-sectional study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
12 Feb 2021
12 Feb 2021
Historique:
received:
25
11
2019
accepted:
22
12
2020
entrez:
13
2
2021
pubmed:
14
2
2021
medline:
25
2
2021
Statut:
ppublish
Résumé
To investigate whether chemical shift imaging (CSI) is useful for differentiating myelomatous infiltration from hematopoietic bone marrow (BM) and for quantitatively assessing disease severity.In this retrospective study, spinal MRI, including a sagittal iterative decomposition of water and fat with echo asymmetry and least-squares estimation T2 fast spin-echo sequence, was performed on 76 myeloma patients (45 men, 67.0 ± 11.4 years; 31 women, 66.5 ± 11.0 years) and 30 control subjects (20 men, 67.0 ± 8.4 years; 10 women, 67.0 ± 9.2 years). The fat-signal fraction (FF) and mean signal dropout ratio (DR) were calculated from lumbar BM that contained no focal lesions. The BM plasma cell percentage (BMPC%) and serological data were obtained. As DR is highest when FF = 50%, the patients were divided into 2 groups: a water-dominant group (FF < 50%) and a fat-dominant group (FF > 50%).Serum monoclonal protein (M protein), β2-microglobulin, and BMPC% were significantly higher in the water-dominant group than in the fat-dominant group. In the water-dominant group, DR correlated significantly with BMPC% and M protein, whereas in the control group, DR showed a weak correlation with age but no correlation with other clinical factors. No significant differences in any clinical data were seen between high and low DR.CSI proved ineffective for differentiating myelomatous infiltration from hematopoietic BM. For myeloma patients with relatively high BM cellularity, a small signal drop on opposed-phase images indicated a higher tumor burden. For BM with relatively low cellularity, disease severity was not reflected by CSI.
Identifiants
pubmed: 33578532
doi: 10.1097/MD.0000000000024358
pii: 00005792-202102120-00025
pmc: PMC7886478
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24358Subventions
Organisme : KAKENHI
ID : 17K10406
Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
M.T.: Kyowa Kirin Co., Ltd., Celgene Co.; K.A.: Research grants from Canon Medical Systems Corporation, Hitachi Ltd., Fujitsu Ltd., Eisai Co., Ltd., Nemoto Kyorindo Co., Ltd., and Fuji Pharma Co., Ltd. Remaining authors have no conflicts of interest to disclose.
Références
Moulopoulos LA, Gika D, Anagnostopoulos A, et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 2005;16: 1824-1328.
Lecouvet FE, Vande Berg BC, Michaux L, et al. Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging. Radiology 1998;209:653–60.
Moulopoulos LA, Dimopoulos MA, Kastritis E, et al. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. Am J Hematol 2012;87:861–4.
Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in wholebody magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28:1606–10.
Dixon WT. Simple proton spectroscopic imaging. Radiology 1984;153:189–94.
Zajick DC Jr, Morrison WB, Schweitzer ME, et al. Benign and malignant processes: normal values and differentiation with chemical shift MR imaging in vertebral marrow. Radiology 2005;237:590–6.
Costa FM, Canella C, Vieira FG, et al. The usefulness of chemical-shift magnetic resonance imaging for the evaluation of osteoid osteoma. Radiol Bras 2018;51:156–61.
Swartz PG1, Roberts CC. Radiological reasoning: bone marrow changes on MRI. AJR Am J Roentgenol 2009;193:S1–4.
Reeder SB, Pineda AR, Wen Z, et al. Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): application with fast spin-echo imaging. Magn Reson Med 2005;54:636–44.
Guiu B, Petit JM, Loffroy R, et al. Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 2009;250:95–102.
Hines CD, Yu H, Shimakawa A, et al. Quantification of hepatic steatosis with 3-T MR imaging: validation in ob/ob mice. Radiology 2010;254:119–28.
Takasu M, Tani C, Sakoda Y, et al. Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results. Eur Radiol 2012;22:1114–21.
Takasu M, Tamura T, Kaichi Y, et al. Magnetic resonance evaluation of multiple myeloma at 3.0 Tesla: how do bone marrow plasma cell percentage and selection of protocols affect lesion conspicuity? PLoS One 2014;28:e85931.
Aoki T, Yamaguchi S, Kinoshita S, et al. Quantification of bone marrow fat content using iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): reproducibility, site variation and correlation with age and menopause. Br J Radiol 2016;89:20150538.
International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies: multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749–57.
Vogler JB 3rd, Murphy WA. Bone marrow imaging. Radiology 1988;168:679–93.
Palumbo A, Waage A, Hulin C, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica 2013;98:87–94.
Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 2013;98:980–7.
Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328–46.
Swartz PG, Roberts CC. Radiological reasoning: bone marrow changes on MRI. AJR Am J Roentgenol 2009;193:S1–4.
Koutoulidis V, Fontara S, Terpos E, et al. Quantitative Diffusion-weighted imaging of the bone marrow: an adjunct tool for the diagnosis of a diffuse MR imaging pattern in patients with multiple myeloma. Radiology 2017;282:484–93.
Koutoulidis V, Papanikolaou N, Moulopoulos LA. Functional and molecular MRI of the bone marrow in multiple myeloma. Br J Radiol 2018;91:20170389.
Yu H, McKenzie CA, Shimakawa A, et al. Multiecho reconstruction for simultaneous water-fat decomposition and T2∗ estimation. J Magn Reson Imaging 2007;26:1153–61.
Yu H, Shimakawa A, McKenzie CA, et al. Multiecho water-fat separation and simultaneous R2∗ estimation with multifrequency fat spectrum modeling. Magn Reson Med 2008;60:1122–34.
Colgan TJ, Van Pay AJ, Sharma SD, et al. Diurnal variation of proton density fat fraction in the liver using quantitative chemical shift encoded MRI. J Magn Reson Imaging 2020;51:407–14.
Procter AJ, Sun JY, Malcolm PN, et al. Measuring liver fat fraction with complex based chemical shift MRI: the effect of simplified sampling protocols on accuracy. BMC Medical Imaging 2019;19:14.